Lexaria Bioscience Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lexaria Bioscience Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $705.9K | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $464.3K | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $226.2K | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $255.4K | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $722.7K | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $314.8K | Nov 29, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Aug 31, 2024 | $464.3K | Nov 26, 2024 |
| FY2024 | Aug 31, 2023 | $226.2K | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $255.4K | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $722.7K | Nov 28, 2022 |
| FY2020 | Aug 31, 2020 | $384.5K | Oct 15, 2020 |
| FY2020 | Aug 31, 2019 | $222.6K | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | $433.3K | Nov 14, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $703.2K | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $459.5K | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $194.7K | Nov 26, 2024 |
| FY2023 | May 11, 2023 | $538.3K | Nov 20, 2023 |
| FY2023 | Aug 31, 2022 | $183.6K | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $547.4K | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $215.4K | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | $199.7K | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | $408.1K | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | $33.9K | Nov 14, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($11.90M) | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | ($5.80M) | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | ($6.66M) | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | ($7.27M) | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | ($4.03M) | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | ($4.08M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($4.16M) | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | ($6.61M) | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | ($1.93M) | Nov 14, 2018 |
| FY2018 | Aug 31, 2016 | ($1.28M) | Nov 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($11.88M) | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | ($5.75M) | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | ($6.53M) | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | ($6.62M) | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | ($5.69M) | Nov 28, 2022 |
| FY2016 | Aug 31, 2016 | ($1.28M) | Nov 29, 2016 |
| FY2016 | Aug 31, 2015 | ($1.98M) | Nov 29, 2016 |
| FY2015 | Aug 31, 2014 | ($1.56M) | Nov 27, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $8.24M | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $2.36M | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $3.67M | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $1.84M | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $1.26M | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $387.1K | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | $555.7K | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | $492.9K | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | $54.2K | Nov 14, 2018 |
| FY2018 | Aug 31, 2016 | $9.0K | Nov 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($10.45M) | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | ($4.96M) | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | ($5.88M) | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | ($4.88M) | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | ($3.99M) | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | ($2.62M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($3.01M) | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | ($2.52M) | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | ($1.55M) | Nov 14, 2018 |
| FY2018 | Aug 31, 2016 | ($660.9K) | Nov 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $24.6K | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $43.0K | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $33.7K | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $49.2K | Nov 20, 2023 |
| FY2020 | Aug 31, 2020 | $0 | Oct 15, 2020 |
| FY2020 | Aug 31, 2019 | $646.2K | Oct 15, 2020 |
| FY2017 | Aug 31, 2017 | $0 | Nov 27, 2017 |
| FY2018 | Aug 31, 2016 | $3.1K | Nov 14, 2018 |
| FY2016 | Aug 31, 2015 | $0 | Nov 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $4.18M | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $8.87M | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $3.08M | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $7.83M | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $13.27M | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $2.83M | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | $2.68M | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | $2.43M | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | $2.86M | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | $566.6K | Nov 27, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.57M | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $1.21M | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $403.9K | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $201.4K | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $203.3K | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $346.0K | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | $184.5K | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | $43.6K | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | $92.3K | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | $478.9K | Nov 27, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.99M | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | $8.04M | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | $3.04M | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | $7.95M | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | $13.27M | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $2.48M | Nov 29, 2021 |
| FY2021 | Aug 31, 2019 | $2.49M | Nov 29, 2021 |
| FY2019 | Aug 31, 2018 | $2.39M | Nov 14, 2019 |
| FY2019 | Aug 31, 2017 | $2.77M | Nov 14, 2019 |
| FY2017 | Aug 31, 2016 | $266.0K | Nov 27, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($63.46M) | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | ($51.56M) | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | ($45.76M) | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | ($39.10M) | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | ($31.83M) | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | ($27.80M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($23.87M) | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | ($19.77M) | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | ($13.17M) | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | ($11.30M) | Nov 27, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Aug 31, 2022 | $5.81M | Nov 28, 2022 |
| FY2022 | Aug 31, 2021 | $10.92M | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | $1.29M | Nov 29, 2021 |
| FY2021 | Aug 31, 2019 | $1.29M | Nov 29, 2021 |
| FY2020 | Aug 31, 2018 | $1.73M | Oct 15, 2020 |
| FY2019 | Aug 31, 2017 | $2.53M | Nov 14, 2019 |
| FY2018 | Aug 31, 2016 | $93.4K | Nov 14, 2018 |
| FY2018 | Aug 31, 2015 | $260.1K | Nov 14, 2018 |
| FY2016 | Aug 31, 2014 | $703.0K | Nov 29, 2016 |
| FY2013 | Oct 31, 2013 | $65.5K | Jan 24, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 0 | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | (1) | Nov 26, 2024 |
| FY2011 | Oct 31, 2011 | 0 | Jan 30, 2012 |
| FY2011 | Oct 31, 2010 | 0 | Jan 30, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 19.56M | Nov 28, 2025 |
| FY2025 | Aug 31, 2024 | 15.81M | Nov 28, 2025 |
| FY2024 | Aug 31, 2023 | 8.09M | Nov 26, 2024 |
| FY2023 | Aug 31, 2022 | 5.95M | Nov 20, 2023 |
| FY2022 | Aug 31, 2021 | 5.73M | Nov 28, 2022 |
| FY2021 | Aug 31, 2020 | 3.00M | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | 78.79M | Oct 15, 2020 |
| FY2019 | Aug 31, 2018 | 75.53M | Nov 14, 2019 |
| FY2018 | Aug 31, 2017 | 67.98M | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | 51.29M | Nov 27, 2017 |